BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Chen J, Li X, Xu S, Zhang M, Wu Z, Zhang X, Xu Y, Chen Y. Delayed PARP-1 Inhibition Alleviates Post-stroke Inflammation in Male Versus Female Mice: Differences and Similarities. Front Cell Neurosci 2020;14:77. [PMID: 32317937 DOI: 10.3389/fncel.2020.00077] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
Number Citing Articles
1 Paul S, Candelario-Jalil E. Emerging neuroprotective strategies for the treatment of ischemic stroke: An overview of clinical and preclinical studies. Exp Neurol 2021;335:113518. [PMID: 33144066 DOI: 10.1016/j.expneurol.2020.113518] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
2 Lynch MA. Exploring Sex-Related Differences in Microglia May Be a Game-Changer in Precision Medicine. Front Aging Neurosci 2022;14:868448. [DOI: 10.3389/fnagi.2022.868448] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
3 Vallerini GP, Cheng YH, Chase KA, Sharma RP, Kusumo H, Khakhkhar S, Feinstein DL, Guizzetti M, Gavin DP. Modulation of Poly ADP Ribose Polymerase (PARP) Levels and Activity by Alcohol Binge-Like Drinking in Male Mice. Neuroscience 2020;448:1-13. [PMID: 32920042 DOI: 10.1016/j.neuroscience.2020.09.010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
4 Rocchi D, Blázquez-Barbadillo C, Agamennone M, Laghezza A, Tortorella P, Vicente-Zurdo D, Rosales-Conrado N, Moyano P, Pino JD, González JF, Menéndez JC. Discovery of 7-aminophenanthridin-6-one as a new scaffold for matrix metalloproteinase inhibitors with multitarget neuroprotective activity. Eur J Med Chem 2021;210:113061. [PMID: 33310289 DOI: 10.1016/j.ejmech.2020.113061] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Mekhaeil M, Dev KK, Conroy MJ. Existing Evidence for the Repurposing of PARP-1 Inhibitors in Rare Demyelinating Diseases. Cancers 2022;14:687. [DOI: 10.3390/cancers14030687] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
6 Liu S, Luo W, Wang Y. Emerging role of PARP-1 and PARthanatos in ischemic stroke. J Neurochem 2021. [PMID: 34241907 DOI: 10.1111/jnc.15464] [Reference Citation Analysis]
7 Wang Y, Pleasure D, Deng W, Guo F. Therapeutic Potentials of Poly (ADP-Ribose) Polymerase 1 (PARP1) Inhibition in Multiple Sclerosis and Animal Models: Concept Revisiting. Adv Sci (Weinh) 2022;9:e2102853. [PMID: 34935305 DOI: 10.1002/advs.202102853] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Arruri VK, Gundu C, Khan I, Khatri DK, Singh SB. PARP overactivation in neurological disorders. Mol Biol Rep 2021;48:2833-41. [PMID: 33768369 DOI: 10.1007/s11033-021-06285-1] [Reference Citation Analysis]
9 Lu P, Zhang Y, Niu H, Wang Y. Upregulated Long Non-coding RNA ALMS1-IT1 Promotes Neuroinflammation by Activating NF-κB Signaling in Ischemic Cerebral Injury. Curr Pharm Des 2021;27:4270-7. [PMID: 34455967 DOI: 10.2174/1381612827666210827104316] [Reference Citation Analysis]